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A B S T R A C T
Purpose
Cancer-inducedbonepain (CIBP) affects one third of patientswith cancer. Radiotherapy remains the gold-
standard treatment; however, laboratory and clinicalwork suggest that pregabalinmaybeuseful in treating
CIBP. The aim of this study was to examine pregabalin in patients with CIBP receiving radiotherapy.
Patients and Methods
A multicenter, double-blind randomized trial of pregabalin versus placebo was conducted. Eligible
patients were age $ 18 years, had radiologically proven bone metastases, were scheduled to
receive radiotherapy, and had pain scores $ 4 of 10 (on 0-to-10 numeric rating scale). Before
radiotherapy, baseline assessments were completed, followed by random assignment. Doses of
pregabalin and placebo were increased over 4 weeks. The primary end point was treatment
response, deﬁned as a reduction of$ 2 points in worst pain by week 4, accompanied by a stable or
reduced opioid dose, compared with baseline. Secondary end points assessed average pain,
interference of pain with activity, breakthrough pain, mood, quality of life, and adverse events.
Results
A total of 233 patients were randomly assigned: 117 to placebo and 116 to pregabalin. Themost common
cancers were prostate (n5 88; 38%), breast (n5 77; 33%), and lung (n5 42; 18%). In the pregabalin arm,
45 patients (38.8%) achieved the primary end point, comparedwith 47 (40.2%) in the placebo arm (adjusted
odds ratio, 1.07; 95%CI, 0.63 to 1.81;P5 .816). Therewere no statistically signiﬁcant differences in average
pain, pain interference, or quality of life between arms. There were differences in mood (P 5 .031) and
breakthrough pain duration (P 5 .037) between arms. Outcomes were compared at 4 weeks.
Conclusion
Our ﬁndings do not support the role of pregabalin in patients with CIBP receiving radiotherapy. The
role of pregabalin in CIBP with a clinical neuropathic pain component is unknown.
J Clin Oncol 34:550-556. © 2015 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Cancer-induced bone pain (CIBP) is the most
common type of cancer pain, affecting one third
of patients.1,2 CIBP exists as a combination of
background and breakthrough pain, with the
latter either being related to events (eg, physical
activity) or occurring spontaneously without any
obvious precipitating factor.3 In CIBP, this poses a
particular challenge. Standard analgesics (eg, opioids,
nonsteroidal anti-inﬂammatories, bisphosphonates)
may be useful in controlling background pain;
however, they are often ineffective in treating
breakthrough pain.4
Radiotherapy is the gold-standard treatment
for CIBP; however, meta-analyses have demon-
strated that only 25% of patients will achieve
complete pain relief, whereas 41% will achieve
partial pain relief, with onset of analgesia taking
4 to 6 weeks.5 Many patients with CIBP do not
achieve acceptable levels of analgesia.
Animal models have been developed to under-
stand the pathophysiology of CIBP.6 Focal bone
cancer pain models are used currently, and these
provide a robust model (with features similar to
550 © 2015 by American Society of Clinical Oncology
VOLUME 34 • NUMBER 6 • FEBRUARY 20, 2016
Downloaded from ascopubs.org by 131.251.254.68 on December 13, 2017 from 131.251.254.068
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
CIBP in humans). Through these, it has become evident that the
underlying pathophysiology of CIBP differs from that in standard
neuropathic or inﬂammatory pain models, although containing
elements of both as well as involving additional factors arising from
host–cancer cell interactions.7,8 Excitability in dorsal horn sensory
processing pathways is markedly increased, resulting in both elec-
trophysiologic and behavioral hypersensitivity.9 This means that
painful and nonpainful peripheral nerve input (eg, touch, vibration,
thermal stimuli) result in ongoing and stimulus-evoked pain that
can be exacerbated by movement.
Animal models have been used to assess whether agents used
for neuropathic pain could correct the abnormal dorsal horn
neuronal architecture and minimize the central sensitization,
which also exists in CIBP—particularly whether drugs that bind to
the a2-d subunit of calcium channels (eg, pregabalin, gabapentin)
could act to reduce pain transmission. Expression of the a2-d1
subunit in dorsal root ganglia is increased after peripheral nerve
injury, where it is thought to facilitate channel trafﬁcking to the
plasmamembrane and thereby contribute to development of central
sensitization and pain hypersensitivity.10-12 Pregabalin and gaba-
pentin have proven efﬁcacy in a variety of chronic pain models (eg,
nerve injury), probably through a reduction in excitatory neuro-
transmitter release and central sensitization.13 Animal studies have
also reported efﬁcacy in CIBP models, suggesting that pregabalin
and gabapentin may be of value clinically in treating CIBP.9
In the clinical setting, pregabalin is being used increasingly to
treat CIBP.14-17 This may be the result of emerging animal studies
but may also be because of anecdotal ﬁndings. In palliative care,
many of the drugs used in routine clinical practice have limited or
no evidence supporting their use, but they are embedded in clinical
practice. Therefore, it is fundamental that pregabalin be examined
in a robust clinical trial within the relevant population before it
becomes more widely adopted as a treatment for CIBP.
Following this translational paradigm, and given the need to
improve management of CIBP and the need to assess the role of
pregabalin fully in the clinical setting, a randomized double-blind
trial of pregabalin (Lyrica; Pﬁzer, Tadworth, United Kingdom) versus
placebo in conjunction with palliative radiotherapy for CIBP was
conducted. Our hypothesis was that a2-d calcium channel ligands
may have a role in CIBP in humans,mirroring the preclinicalﬁndings.
PATIENTS AND METHODS
Trial Design and Participants
This was a multicenter, double-blind randomized trial of pregabalin
versus placebo in conjunction with palliative radiotherapy for CIBP.
Eligible patients were age$ 18 years, had radiologic evidence of metastatic
bone disease, and were scheduled to receive radiotherapy for$ one site of
clearly identiﬁable bone pain. Other key inclusion criteria were: life
expectancy. 2 months, pain score (worst pain)$ 4 (on 0-to-10 numeric
rating scale [NRS]) at the site of pain, scheduled to be treated with
radiotherapy at that site, and ability to provide written informed consent.
The main exclusion criteria were: current gabapentin or pregabalin use,
signiﬁcant renal impairment (creatinine clearance , 60 mL/min), and
receiving wide-ﬁeld irradiation. Patients who had any change in anticancer
therapy before entering the trial with the potential to inﬂuence pain during
the trial were excluded. Initially, radiotherapy to vertebral sites was an
exclusion criterion, but this was subsequently removed as a major protocol
modiﬁcation, as discussed and approved by the trial steering committee,
after 14 patients had been consented. The trial was conducted in ﬁve cancer
centers in the United Kingdom: the Beatson West of Scotland Cancer
Centre (Glasgow), Edinburgh Cancer Centre (Edinburgh), Velindre Cancer
Centre (Cardiff), Princess Alexandra Tayside Cancer Centre (Dundee), and
Mount Vernon Hospital (London).
Procedures
After giving consent, patients entered a run-in phase (maximum,
2 weeks) where their analgesia was optimized before radiotherapy to
ensure, where possible, there were minimal changes in analgesia after
random assignment and radiotherapy and to allow the effect of the
intervention (pregabalin or placebo) alone to be assessed. In such cases,
Screened for eligibility
(N = 1,970)
Randomly allocated
(n = 233)
Allocated to pregabalin and radiotherapy
(n = 116)
Discontinued intervention
   Unwell during trial
   Died during trial
   Adverse effects
   Withdrew
   Other
(n = 32)
(n = 6)
(n = 6)
(n = 5)
(n = 6)
(n = 9)
Discontinued intervention
   Unwell during trial
   Died during trial
   Adverse effects
   Withdrew
   Other
(n = 24)
(n = 4)
(n = 2)
(n = 5)
(n = 7)
(n = 6)
Allocated to placebo and radiotherapy
(n = 117)
Analyzed
(n = 116)
Analyzed
(n = 117)
Excluded
   Did not meet inclusion 
      criteria
   Refused to participate
   Other reasons
(n = 1,737)
(n = 1,707)
(n = 8)
(n = 22)
Fig 1. CONSORT diagram.
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patients would have stable pain; however, this would still be suboptimal,
necessitating the need for radiotherapy.
Some patients had stable pain control and analgesic requirements
before random assignment. Others had to have analgesics modiﬁed before
random assignment. At the point of receiving radiotherapy, patients were
only randomly assigned if they still met the eligibility criteria, with critically
worst pain score $ 4 (0-to-10 NRS).
The radiotherapy regimen was either 8 Gy in one fraction or 20 Gy in
ﬁve fractions, as per the decision of the patient’s oncologist. Baseline
assessments were performed in the 24 hours before the ﬁrst fraction.
Random assignment was carried out after the baseline assessments and
before radiotherapy. Patients received either pregabalin or placebo and
were given a 35-day supply of medication. Patients were instructed to take
one capsule of the trial medication twice daily (12 hours apart). Each
capsule contained either 75 mg of pregabalin or placebo. The trial
medication was supplied free by Pﬁzer.
Patients were contacted every 2 to 3 days to encourage compliance with
the medication and monitor for any adverse events. Every 7 days from
baseline (days 8, 15, and 22), a formal assessment of analgesia was under-
taken. Where a clinically meaningful improvement in pain had not occurred
(deﬁned as $ 2-point decrease on 0-to-10 NRS and/or patient felt adequate
analgesia had not been achieved), the dose of the trial medication was
increased as follows: baseline (day 1), pregabalin or placebo 75mg twice daily;
day 8, pregabalin or placebo 150mg twice daily; day 15, pregabalin or placebo
225 mg twice daily; and day 22, pregabalin or placebo 300 mg twice daily.
End Points
End points were assessed at 1, 2, 3, and 4 weeks after the ﬁrst fraction of
radiotherapy. Analyses relate to assessments at 4 weeks unless otherwise stated.
The primary end point was improvement in CIBP at the site of
radiotherapy by week 4. An improvement was a reduction of$ 2 points on
a 0-to-10 NRS for worst pain, accompanied by a stable or reduced opioid
medication dose, compared with baseline. A decrease of$ 2 points on a 0-
to-10 NRS is accepted as a clinically meaningful improvement in pain in
studies of analgesic interventions and is in keeping with guidelines on end
points in clinical trials in bone metastases.18,19
Secondary end points included: assessment of worst and average pain,
assessment of functional interference of pain in day-to-day living (using
Brief Pain Inventory [BPI]),20 analgesic requirements, tolerability of
pregabalin, global quality-of-life scores (using EuroQol thermometer),21
and mood (using Hospital Anxiety and Depression Scale [HADS]).22
Statistical Analysis
This analysis was based on the objective of showing superiority of
pregabalin versus placebo in improving CIBP using the primary end point.
An intention-to-treat approach was used.
The null hypothesis tested was that there was no difference in
analgesia between the trial arms. A sample size of 206 patients was planned,
based on the assumption that 50% of patients in the placebo arm would
improve (ie, experience $ 2-point drop in worst pain score against
background of stable or reduced opioid dose). To detect an improvement
to 70% (ie, treatment effect of 20%) in the pregabalin arm, 103 patients
were required to complete each arm, using a two sided x2 test with a of
0.05% and 80% power.
The primary analysis used a conservative approach, where any patient
who did not complete the trial was assumed not to have achieved the
primary end point of $ 2-point drop in worst pain score against a
background of stable or reduced opioid dose. This meant that all randomly
assigned patients could be included in the primary intention-to-treat
analysis. However, this approach tends to attenuate any true treatment
effect, so the target sample size was increased to 260. This would give 80%
power at the 5% signiﬁcance level to detect a more conservative treatment
effect of 18%. The safety population included all patients who received any
dose of the trial medication, and adverse event reporting was continued
until 30 days after trial completion.
Random assignment was implemented by the Cancer Research UK
Clinical Trials Unit Glasgow using a minimization algorithm with a
random element, based on: fractionation regimes (single v multiple),
cancer type (breast or prostate v other tumor types), and site of bone
metastasis (vertebrae v nonvertebrae).
Statistical analyses were performed using IBM SPSS (version 19;
SPSS, Chicago, IL). The primary end point (ie, treatment response) was
analyzed using logistic regression, adjusting for the three factors speciﬁed
in the minimization algorithm. The continuous secondary outcome
measures were examined using analysis of covariance, adjusting for the
baseline value of the measure together with the three minimization factors.
Treatment effects are reported as adjusted point estimates together with the
corresponding 95% CIs and P values. No interim analyses were performed.
The trial had ethics committee approval (United Kingdom
07/MRE00/59) and was conducted in accordance with the Declaration
of Helsinki. It was registered with the European Union Drug Regulating
Authorities Clinical Trials and ISRCTN databases.
RESULTS
From August 13, 2008, to April 30, 2012, 233 patients were
randomly assigned. The trial was stopped early (after 233 patients
had been randomly assigned [target, n5 260]) on the basis of slow
recruitment, evidenced by the fact that only one in eight patients
screened was consented, as seen in the CONSORT diagram (Fig 1).
The main reasons patients were unable to participate were poor
renal function (19.0%), patient declined (8.7%), concomitant use
of pregabalin or gabapentin (6.9%), or insufﬁcient pain (4.5%).
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
Pregabalin
Arm*
(n 5 116)
Placebo Arm
(n 5 117)
No. % No. %
Age, years
# 44 5 4.3 5 4.3
45-64 57 49.6 47 40.2
$ 65 53 46.1 65 55.6
Male sex 59 50.9 71 60.7
Primary cancer type
Bladder 1 0.9 4 3.4
Bone 1 0.9 0 0
Breast 41 35.3 36 30.8
GI 5 4.4 6 5.3
Renal 1 0.9 0 0
Larynx 1 0.9 0 0
Lung 23 19.8 19 16.2
Myeloma 0 0 1 0.9
Prostate 41 35.3 47 40.2
Skin 0 0 1 0.9
Unknown 2 1.7 3 2.6
Pain assessment at baseline
BPI Intensity (0-40)
Mean 18.63 18.68
SD 7.51 6.58
BPI Interference (0-70)
Mean 39.90 36.48
SD 16.30 14.54
BPI Total (0-130)
Mean 59.95 59.03
SD 20.18 18.62
Abbreviations: BPI, Brief Pain Inventory; SD, standard deviation.
*Data on age are missing for one patient in the pregabalin arm.
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Patient demographics are listed in Table 1. One hundred twenty-
seven patients (55%) were male, and the mean age (6 standard devi-
ation) was 65.5 (6 10.97) and 63.7 (6 11.25) years for the placebo and
pregabalin arms, respectively. Prostate (n5 88; 38%), breast (n5 77;
33%), and lung (n5 42; 18%) were the most common cancer types.
Baseline characteristics were similar between the groups.
In the pregabalin arm, 45 patients (38.8%) achieved the
primary end point, compared with 47 (40.2%) in placebo arm
(adjusted odds ratio, 1.07; 95% CI, 0.63 to 1.81; P 5 .816). The
observed absolute difference in response rates was 1.4% in favor of
placebo (40.2% v 38.8%), with a 95% CI ranging from 13.9% in
favor of placebo to 11.2% in favor of pregabalin. In the pregabalin
group, 18 patients (15.5%) did not achieve the 2-point reduction in
worst pain but rather remained on a stable or decreased opioid
dose; 21(18.1%) had an increase in opioid dose, and 32 (27.6%)
could not be assessed (assumed nonresponse). In the placebo
group, 14 patients (11.9%) did not achieve the 2-point reduction in
worst pain but instead remained on a stable or decreased opioid
dose; 31 (26.5%) had an increase in opioid dose, and 25 (21.4%)
could not be assessed (assumed nonresponse).
Figure 2Adetails theworst pain frombaseline to endpoint (week 4)
per trial arm. There were no statistically signiﬁcant differences between
trial arms. The adjusted difference in mean worst pain scores between
trial arms was 20.13 (95% CI, 21.02 to 0.75; P 5 .769).
Figure 2B details the average pain from baseline to end point
(week 4) per trial arm. There were no statistically signiﬁcant
differences between trial arms. The adjusted difference in mean
average pain scores was 20.52 (95% CI, 21.22 to 0.19; P 5 .150).
Table 2 summarizes the BPI Intensity and Interference sub-
scale, HADS, and EuroQol scores between trial arms. The adjusted
mean difference between arms for BPI Intensity score was 20.7
(95% CI, 23.5 to 2.1; P 5 .606). The adjusted mean difference
between trial arms for BPI Interference score was 21.8 (95%
CI, 27.4 to 3.9; P 5 .537). There was a difference in HADS score
between study arms (21.1; 95% CI,22.1 to 0.1; P5 .031), but no
difference in Euroqol score (P 5 .825).
Table 3 lists the serious and common adverse events (AEs)
between trial arms. Fifty-one serious AEs were reported: 27 (53%)
in the pregabalin arm and 24 (43%) in the placebo arm. Only one
serious AE was thought to be related to pregabalin. The most
common AE in the pregabalin arm was cognitive disturbance
(23 events).
Table 4 lists breakthrough pain characteristics. These were
similar between arms, with the exception of duration of break-
through pain episodes, which was lower in the pregabalin arm
(P 5 .037).
DISCUSSION
This large clinical trial does not demonstrate an analgesic beneﬁt
from pregabalin in patients with CIBP receiving radiotherapy.
Individual pain measures were similar across both arms, and the
consistency of neutral primary and secondary end points supports
that the study was sufﬁciently powered to detect a difference.
Despite the trial under-recruiting, the primary result comfortably
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Fig 2. (A) Worst and (B) average pain per treatment arm from baseline to week 4 (by week). Adjusted difference mean (adjusted for three randomization stratiﬁcation
factors: fractionation regimen, cancer type, and site of bone metastasis): (A) 20.13 (95% CI, 21.02 to 0.75; P 5 .769) and (B) 20.52 (95% CI, 21.22 to 0.19; P 5 .150).
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excludes the 20% advantage to pregabalin, which was the basis of
the power calculation, and indeed, the 95% CIs were compatible
with, at most, an 11.2% improvement in response rate, which
would not be clinically meaningful.18,19
Of note, patients in the pregabalin arm experienced
improvements in mood and reduced duration of breakthrough
pain episodes. However, these must be considered in the context of
the large CIs present and the established role of pregabalin for
treating anxiety.
The current ﬁndings will have considerable implications for
clinical practice, because pregabalin is being used increasingly in
the setting of CIBP. Although basic science work was encouraging,
with a possible therapeutic role for a2-d calcium channel ligands in
rodent models of CIBP, there had been limited clinical validation.9
A case report examined gabapentin in CIBP and suggested possible
beneﬁt.14 It was followed by a randomized trial of pregabalin versus
placebo, which suggested potential value of pregabalin in CIBP,
although ﬁrm conclusions could not be drawn.15 Another study
suggested pregabalin in combination with mirtazapine may be
beneﬁcial; however, it advised additional trials.16 Nevertheless,
despite the limited evidence, pregabalin is often prescribed for
CIBP, with some reviews of CIBP management recommending the
use of pregabalin if there is a neuropathic component to the pain.17
However, our ﬁndings do not support a role for pregabalin in CIBP,
and we suggest that its clinical role in CIBP be reconsidered.
The challenges of translating laboratory ﬁndings clinically, in
pain, include the difﬁculty in replicating multidimensional pain in
animals and the subjectivity of testing in laboratory conditions.23
In clinical trials of patients with peripheral neuropathic pain,
gabapentinoids have consistently demonstrated signiﬁcant
beneﬁt.24-26 However, only a minority of patients achieved sub-
stantial pain relief, with many not responding. Patients with CIBP
generally have multiple serious morbidities and a more complex
array of factors contributing to their hypersensitivity, as a result of
immunologic responses to the cancer. Their pain state is more
complex and may be less readily reversible by pharmacologic
interventions. Animal models may also not respond to therapeutic
intervention either qualitatively or quantitatively in the same way
as patients with CIBP. These and other reasons may have resulted
in the lack of translation of our ﬁndings seen herein.
The trial had some limitations. All patients had metastatic
cancer, and as such, many had different sites of pain. We focused on
the area of pain corresponding to the radiotherapy site, and pain
assessments were performed accordingly. Also, patients’ overall
conditions were deteriorating, in keeping with the advanced nature
of their disease, and therefore, quality-of-life parameters could
have changed. The end point measures were assessed 4 weeks after
radiotherapy. It has been advocated that the optimal time for
assessing response to radiotherapy for CIBP is 8 weeks, and we
cannot be certain that additional differences would not have been
evident if the trial had assessed end points at this time.27 However,
although there may have been a greater number responding, the
relative difference between the two arms would not be expected to
change across a period from 4 to 8 weeks. The optimal dose of
pregabalin in this setting of advanced cancer is not known, and again,
it could be argued that higher doses or longer trial duration should
have been used. Patients were, however, titrated to the maximum-
tolerated dose, which resulted in 67% of patients achieving a dose
of $ 300 mg daily for at least 3 weeks. These aspects have to be
Table 2. BPI, EuroQol, and HADS Scores Between Treatment Arms
Measure
Baseline End Point (week 4)
No. of
Patients
Score
No. of
Patients
Score Change Difference Adjusted Difference*
Mean SD Mean SD Mean SD Mean 95% CI P Mean 95% CI P
BPI Intensity 20.4 23.3 to 2.4 .762 20.7 23.5 to 2.1 .606
Pregabalin 115 18.6 7.5 85 9.5 9.1 8.3 10.5
Placebo 114 18.7 6.6 94 10.1 7.7 8.7 8.6
BPI Interference 21.4 27.0 to 4.2 .629 21.8 27.4 to 3.9 .537
Pregabalin 110 37.9 16.3 80 24.2 19.3 9.9 18.4
Placebo 113 36.5 14.5 90 26.0 18.3 11.3 18.0
EuroQol 20.6 28.0 to 6.8 .868 20.8 28.2 to 6.6 .825
Pregabalin 114 54.6 19.6 86 60.1 24.1 3.8 24.1
Placebo 113 55.3 19.6 92 60.2 23.0 4.4 25.5
HADS 21.0 22.0 to 20.1 .039 21.1 22.1 to 20.1 .031
Pregabalin 105 19.8 3.3 82 20.8 3.0 20.8 3.3
Placebo 112 20.7 3.0 88 20.5 3.1 0.2 3.1
Abbreviations: BPI, Brief Pain Inventory; HADS, Hospital Anxiety and Depression Scale; SD, standard deviation.
*Adjusted for three randomization stratiﬁcation factors: fractionation regimen, cancer type, and site of bone metastasis.
Table 3. Adverse Events
Adverse Event
No. (%)
Pregabalin Arm Placebo Arm
Serious
No. of events (n 5 51) 27 (53) 24 (47)
Expected* 19 (37) 11 (22)
Likely related to IMP† 1 (2) 2 (4)
Common
No. of events (n 5 266)‡ 183 (67) 83 (31)
Nausea 15 (6) 21 (8)
Cognitive disturbance 23 (9) 8 (3)
Vomiting 9 (3) 8 (3)
Fatigue 11 (4) 8 (3)
Pain 8 (3) 10 (4)
Abbreviation: IMP, investigational medicinal product.
*In keeping with underlying disease.
†In opinion of investigator.
‡Most common events.
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considered in the context of high attrition, which may have
increased further with longer trial duration. We also acknowledge
that patients who have CIBP with neuropathic features may be
more likely to beneﬁt from pregabalin than those without;
however, this was outside the scope of our trial. In our trial, we looked
at those patients referred to radiation oncology for consideration of
palliative radiotherapy for uncontrolled CIBP. Clearly, patients treated
successfully with pregabalin or gabapentin, because of CIBP with
clinical neuropathic features, would not have reached radiation
oncology and therefore screening in this study. Undertaking pain
trials in in patients with cancer is challenging, but our trial
succeeded by using a rigorous, well-designed protocol, a small
number of centers, and focused patient follow-up.
Despite the neutral ﬁndings, we support the opinion of Hardy
et al28 on the need for trials in patients with advanced cancer.
Currently, the majority of symptom control practice is based on
either historical anecdote or low-level evidence, and the lack of
research is paradoxical to its importance.29 There is a need for well-
designed clinical trials that either support or (as in our trial) refute
practice.We have demonstrated that undertaking symptom control
trials in patients with cancer is feasible.
In conclusion, our ﬁndings do not support the role of pre-
gabalin in patients receiving radiotherapy for CIBP. Future trials
examining pregabalin in CIBP with a neuropathic pain component
would be of interest.
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Table 4. Breakthrough Pain
Feature
Pregabalin Arm (n 5 45) Placebo Arm (n 5 54)
P*No. % No. %
No. of episodes .230
0-3 30 67 30 56
4-6 6 13 12 22
. 7 8 18 6 11
Unknown 1 2 6 11
Severity (0-10 NRS) .175
0-3 19 46 15 29
4-6 10 24 16 31
. 7 12 29 20 39
Duration of episode, minutes .037
, 1 7 21.88 4 8.51
1-15 17 53.13 19 40.43
16-30 5 15.63 12 25.53
31-60 1 3.13 5 10.64
60-120 0 0.00 2 4.26
. 120 2 6.25 5 10.64
Time from onset to maximum intensity .123
Unpredictable 11 34.38 11 22.92
, 10 seconds 11 34.38 9 18.75
10 seconds to 5 minutes 6 18.75 16 33.33
6-30 minutes 4 12.50 10 20.83
31-60 minutes 0 0.00 2 4.17
Predictability .657
Never 15 39.47 21 41.18
Sometimes 15 39.47 16 31.37
Often 0 0.00 3 5.88
Almost always 2 5.26 7 13.73
Always 6 15.79 4 7.84
Use of analgesia .266
Every time 8 21.05 8 16.00
Most of the time 9 23.68 13 26.00
Some of the time 6 15.79 16 32.00
Hardly ever 9 23.68 6 12.00
Never 6 15.79 7 14.00
Abbreviation: NRS, numeric rating scale.
*Mann-Whitney test.
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